Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine ...
Analysis of eight clinical trials showed CDK4/6 inhibitors combined with endocrine therapy significantly improved progression-free survival (PFS) and overall survival (OS) in advanced breast cancer patients, compared to endocrine therapy alone. Adverse events like bone marrow suppression increased, but gastrointestinal toxicity did not. The study underscores the efficacy and safety of CDK4/6 inhibitors in breast cancer treatment.
Reference News
Analysis of eight clinical trials showed CDK4/6 inhibitors combined with endocrine therapy significantly improved progression-free survival (PFS) and overall survival (OS) in advanced breast cancer patients, compared to endocrine therapy alone. Adverse events like bone marrow suppression increased, but gastrointestinal toxicity did not. The study underscores the efficacy and safety of CDK4/6 inhibitors in breast cancer treatment.